Novel dual-target μ‑opioid and TRPV1 ligands as potential pharmacotherapeutics for pain management
- 23 December 2022
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 131, 106335
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- How opioid drugs bind to receptorsNature, 2012
- Activation of TRPV1 Contributes to Morphine Tolerance: Involvement of the Mitogen-Activated Protein Kinase Signaling PathwayThe Journal of Neuroscience, 2008
- Identification of (R)-1-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a Potent TRPV1 Antagonist for Pain ManagementJournal of Medicinal Chemistry, 2008
- Opioid and melanocortin receptors: Do they have overlapping pharmacophores?Biopolymers, 2007
- Novel Vanilloid Receptor-1 Antagonists: 3. The Identification of a Second-Generation Clinical Candidate with Improved Physicochemical and Pharmacokinetic PropertiesJournal of Medicinal Chemistry, 2007
- NSAID-Associated Adverse Effects and Acid Control Aids to Prevent ThemDrug Safety, 2006
- Adaptation of Aequorin Functional Assay to High Throughput ScreeningSLAS Discovery, 2002
- The formalin test: an evaluation of the methodPain, 1992
- Opiate Receptor: Demonstration in Nervous TissueScience, 1973
- Semiconductivity of ChlorpromazineNature, 1961